Literature DB >> 6784622

Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis.

J M Dickinson, D A Mitchison.   

Abstract

Model systems were set up in vitro to explore the reasons why rifampin is a better sterilizing drug than isoniazid in short-course chemotherapy of tuberculosis. When the growth rate of Mycobacterium tuberculosis strain H37Rv was reduced uniformly by lowering the incubation temperature or the pH of the culture medium, the bactericidal activity of rifampin and isoniazid decreased to a similar extent. However, when a culture was maintained at 8 degrees C and incubated for daily periods of 1 or 6 h at 37 degrees C, rifampin killed more rapidly than isoniazid. Maintenance of control cultures without antimicrobials at 8 degrees C with or without periods at 37 degrees C, had little or no effect on their viability, ability to commence logarithmic growth at 37 degrees C, or to incorporate [14C]uridine. Old cultures left undisturbed or to which small additions of fresh culture medium were regularly added were killed more rapidly by rifampin than by isoniazid. These experiments supported the view that the special part of the bacterial population that is killed more rapidly by rifampin than by isoniazid during short-course chemotherapy consists of bacilli dormant much of the time but occasionally metabolising for short periods.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6784622     DOI: 10.1164/arrd.1981.123.4.367

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  36 in total

1.  Immunological and pathological comparative analysis between experimental latent tuberculous infection and progressive pulmonary tuberculosis.

Authors:  A K Arriaga; E H Orozco; L D Aguilar; G A W Rook; R Hernández Pando
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

2.  Transcription of the stationary-phase-associated hspX gene of Mycobacterium tuberculosis is inversely related to synthesis of the 16-kilodalton protein.

Authors:  Y Hu; A R Coates
Journal:  J Bacteriol       Date:  1999-03       Impact factor: 3.490

3.  Effects of recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin on infections of mouse peritoneal macrophages with Listeria monocytogenes and Mycobacterium microti in vitro.

Authors:  M Khor; D B Lowrie; D A Mitchison
Journal:  Br J Exp Pathol       Date:  1986-10

Review 4.  Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 5.  Tuberculosis pharmacotherapy: strategies to optimize patient care.

Authors:  Carole D Mitnick; Bryan McGee; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2009-02       Impact factor: 3.889

Review 6.  Dormancy of Mycobacterium tuberculosis and latency of disease.

Authors:  L G Wayne
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

7.  Transcription of two sigma 70 homologue genes, sigA and sigB, in stationary-phase Mycobacterium tuberculosis.

Authors:  Y Hu; A R Coates
Journal:  J Bacteriol       Date:  1999-01       Impact factor: 3.490

8.  A clinical approach to paediatric tuberculosis in Canada.

Authors:  Ian Kitai; Patricia Malloy
Journal:  Paediatr Child Health       Date:  2003-03       Impact factor: 2.253

9.  An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence.

Authors:  L G Wayne; L G Hayes
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

10.  Pharmacokinetic mismatch of tuberculosis drugs.

Authors:  Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2012-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.